Clinical efficacy of paliperidone controlled release tablets and its influence on serum prolactin level in patients with acute schizophrenia
WANG Zong-qin
WANG Gao-hua
WANG Hui-ling
WANG Xiao-ping
Abstract：Objective: To investigate the clinical efficacy of paliperidone and its influence on serum prolac-tin in patients with acute shizophrenia. Methods: Thirty acute schizophrenia patients were administrated with paliperidone controlled release tablets for 8 weeks. The curative effects, social function and adverse reactions were e-valuated with the positive and negative syndrome scale (PANSS) , the Personal and Social Performance (PSP) scale, Barnes scale(BARS) , Extrapyramidal side effects scale(SAS) and involuntary movement scale(AIMS) before treatment and at day 4, 8, 15, 28 and 57 after administration. Serum prolactin level was measured with radio-immunity assay before treatment and at day 28 and 57. Results: 23 patients completed 8 weeks of treatment and 7 patients dropped out. Compared to the data before treatment, PANSS and PSP at day 4, 8, 15 , 28 and 57 had obvious difference (P <0. 01). Only 3 patients had extrapyramidal side effects during the treatment. The serum prola-tin level was higher than that before treatment. No galactorrhea, menostasia and mastauxy were obtained in male patients. Conclusion: Paliperidone controlled release tablet is a new type antipsychotic with high curative efficacy and less side effects. It can elevate the serum prolatin, but there is no prolactin-related adverse reactions. Paliperidone controlled release tablet provides a valuable new treatment option for schizophrenia.
Keywords：paliperidoneschizophreniaacute stageserum prolactin
Publication Date：2009-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 2052-2055 )